ABC | Volume 114, Nº1, Janeiro 2020

Posicionamento Posicionamento da Sociedade Brasileira de Cardiologia e da Sociedade Brasileira de Hemodinâmica e Cardiologia Intervencionista sobre Centro de Treinamento e Certificação Profissional em Hemodinâmica e Cardiologia Intervencionista – 2020 Arq Bras Cardiol. 2020; 114(1):137-193 31. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr.; AmericanCollegeofCardiology/AmericanHeartAssociationTaskForceon Practice Guidelines. 2014 AHA/ACC/HRS guideline for themanagement of patients with atrial fibrillation: a report of the American College of Cardiology/AmericanHeart Association Task Force on PracticeGuidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64(21):e1-76. 32. Kirchhof P, Benussi S, Kotecha D, Ahison A, Atar D, Casadei B, et al. ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016; 37(38):2893-962. 33. O'Brien EC, Holmes DN, Ansell JE, Allen LA, Hylek E, Kowey PR, et al. Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Am Heart J. 2014;167(4):601-9.e1. 34. Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg. 1996;61(2):755-9. 35. Reddy VY, Doshi SK, Kar S, Gibson DN, Price MJ, Huber K, et al. PREVAIL and PROTECT AF Investigators. 5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials. J AmColl Cardiol. 2017; 70(24):2964-75. 36. Tzikas A, Holmes DR Jr, Gafoor S,Ruiz CE, Biomstrom-Lundqvist C, Diener HC, et al. Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints, and data collection requirements for clinical studies. Europace. 2017;19(1):4-15. 37. Kavinsky CJ, Kusumoto FM, Bavry AA, Bailey SR, Ellenbogen KA, Hess PL, et al. SCAI/ACC/HRS Institutional and Operator Requirements for Left Atrial Appendage Occlusion. J Am Coll Cardiol. 2016;67(19):2295-305. 38. Meier B, BlaauwY, KhattabAA, Lewalter T, Sievert H, TondoC, et al. EHRA/ EAPCI expert consensus statement on catheter-based left atrial appendage occlusion. EuroIntervention. 2015;10(9):1109-25. 39. Cruz-Gonzalez I, Perez-Rivera A, Lopez-Jimenez R, Rodriguez-Collado J, Martin-Moreiras J, CasconM, et al. Significance of the learning curve in left atrialappendageocclusionwithtwodifferentdevices.CatheterCardiovasc Interv. 2014;83(4):642-6. 40. LedwochJ,KrollmannC,StaubachS,HugM,StrohmH,MudraH.Learning Curve Assessment for Percutaneous Left Atrial Appendage Closure With the WATCHMANOccluder. J Interv Cardiol. 2016;29(4):393-9. 41. Guérios ÊE, Chamié F, Montenegro M,Saad EB, Brito FS Jr, Caramori PA, et al. First results of the Brazilian Registry of Percutaneous Left Atrial Appendage Closure. Arq Bras Cardiol. 2017;109(5):440-7. 42. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez- Sarano M. Burden of valvular heart diseases: a population-based study. Lancet. 2006;368(9540):1005-11. 43. Tarasoutchi F, Montera MW, Ramos AIO,Sampaio RO, Rosa VE, Accorsi TA, et al. Atualização das Diretrizes Brasileiras de Valvopatias: Abordagem das Lesões Anatomicamente Importantes. Arq Bras Cardiol. 2017;109(6 supl 2):1-34. 44. Otto CM, Lind BK, KitzmanDW, Gersh BJ, Siscovick DS. et al. Association of aortic-valve sclerosis with cardiovascular mortality andmorbidity in the elderly. N Engl J Med. 1999;341(3):142-7. 45. Ribeiro HB, Urena M, Allende R, Amat-Santos IJ, Rodes-Cabau J. et al. Balloon-expandable prostheses for transcatheter aortic valve replacement. Prog Cardiovasc Dis. 2014;56(6):583-95. 46. LeonMB, Smith CR, MackM, Miller DC, Moses JW, Svensson LG, et al. et al.; PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010; 363(17):1597-607. 47. Leon MB, Smith CR, Mack MJ, Makkar RR, Svenson LG, Kodall SK, et al. PARTNER 2 Investigators. Transcatheter or Surgical Aortic- Valve Replacement in Intermediate-Risk Patients. N Engl J Med. 2016;374(17):1609-20. 48. Kodali SK, Williams MR, Smith CR, Kapadia S, Pichard AD, Douglas PS, et al.; PARTNER Trial Investigators. Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med. 2012; 366(18):1686-95. 49. Makkar RR, FontanaGP, Jilaihawi H, Kapadia S, PichardAD, Douglas PS, et al. PARTNER Trial Investigators. Transcatheter aortic-valve replacement for inoperable severe aortic stenosis. N Engl J Med. 2012;366(18):1696-704. 50. Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svenson LG, et al. PARTNER Trial Investigators. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med. 2011;364(23):2187-98. 51. Adams DH, Popma JJ, Reardon MJ, Yakubov SJ, Coselli JS, Deeb GM, et al.; U.S. CoreValve Clinical Investigators. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med. 2014; 370(19):1790-8. 52. Reardon MJ, Van Mieghem NM, Popma JJ, Kleiman NS, Sondergaard L, MumtazM, et al.; SURTAVI Investigators. Surgical or Transcatheter Aortic- Valve Replacement in Intermediate-Risk Patients. N Engl J Med. 2017; 376(14):1321-31. 53. Baldus S, Schillinger W, Franzen O,Bekeredjian R, Sievert H, Schofer J, et al.;GermanTranscatheterMitralValve Interventions (TRAMI) investigators. MitraClip therapy in daily clinical practice: initial results from the German transcatheter mitral valve interventions (TRAMI) registry. Eur J Heart Fail. 2012; 14(9):1050-5. 54. Feldman T, Foster E, Glower DD,Kar S, Rinaldi MJ, Fail PS, et al.; EVEREST II Investigators. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med. 2011; 364(15):1395-406. 55. Glower DD, Kar S, Trento A , Lim DS, Bayiwa T, Quesada R, et al. Percutaneous mitral valve repair for mitral regurgitation in high- risk patients: results of the EVEREST II study. J Am Coll Cardiol. 2014;64(2):172-81. 56. Maisano F, Franzen O, Baldus S, Schafer U, Hausleiter J, Butter C, et al. Percutaneous mitral valve interventions in the real world: early and 1-year results from the ACCESS-EU, a prospective, multicenter, nonrandomized post-approval study of theMitraClip therapy in Europe. J AmColl Cardiol. 2013; 62(12):1052-61. 57. Mauri L, Foster E, Glower DD, Apruzzese P, Massaro JM, Herrmann Hc, et al.; EVEREST II Investigators. 4-year results of a randomized controlled trial of percutaneous repair versus surgery for mitral regurgitation. J Am Coll Cardiol. 2013;62(4):317-28. 58. Stone GW, Lindenfeld J, AbrahamWT, Kar S, Lim DS, Mishell JM, et al.; COAPT Investigators. Transcatheter Mitral-Valve Repair in Patients with Heart Failure. N Engl J Med. 2018; 379(24):2307-18. 59. Van den Branden BJ, Swaans MJ, Post MC,Rensing BJ, Eefting FD, Jaarsma W,etal.Percutaneousedge-to-edgemitralvalverepair inhigh-surgical-risk patients: dowe hit the target? JACCCardiovasc Interv. 2012; 5(1):105-11. 60. Therrien J, Siu SC, McLaughlin PR, Liu PP, Williams WG,Webb GD. et al. Pulmonaryvalvereplacement inadults lateafterrepairoftetralogyof fallot: are we operating too late? J Am Coll Cardiol. 2000;36(5):1670-5. 61. d'Udekem Y, Rubay J, Ovaert C. Failure of right ventricular recovery of fallot patients after pulmonary valve replacement: delay of reoperation or surgical technique? J Am Coll Cardiol. 2001;37(7):2008-9. 62. Tweddell JS, Pelech AN, Frommelt PC, Mussatto KA, Wyman JD, Fedderly RT, et al. Factors affecting longevity of homograft valves used in right ventricular outflow tract reconstruction for congenital heart disease. Circulation. 2000;102(19 Suppl 3):III130-5. 63. Feltes TF, Bacha E, Beekman RH3rd, Cheatham JP, Feinstein JA, Gomes AS, et al.; AmericanHeart AssociationCongenital CardiacDefects Committee of the Council onCardiovascular Disease in the Young; Council onClinical Cardiology; Council on Cardiovascular Radiology and Intervention; American Heart Association. Indications for cardiac catheterization and 192